A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of Two Concentrations of SBI-100 Ophthalmic Emulsion in Patients With Elevated Intraocular Pressure
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Tetrahydrocannabinol valine hemisuccinate (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Skye Bioscience
- 09 Aug 2024 According to a Skye Bioscience media release, Research and development (R&D) expenses for the second quarter of 2024 were $4.1 million, as compared to $1.8 million for the same period in 2023. The increase was primarily due to costs associated with the completion of our Phase 2a clinical trial for glaucoma, which has since been discontinued, and the costs from the preparation of the launch of our Phase 2 clinical trial for the treatment of obesity.
- 09 Aug 2024 According to a Skye Bioscience media release, the company has discontinued all clinical development, and research and development related to SBI-100 OE, including its ophthalmology pipeline, and redirected capital resources from its ocular program to its metabolic program.
- 10 Jun 2024 According to a Skye Bioscience media release, the company to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program.